Log in
Log in
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     
Sign up
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     

ALX ONCOLOGY HOLDINGS INC.

(ALXO)
  Report
Delayed Nasdaq  -  04:00 2022-09-26 pm EDT
9.630 USD   -1.63%
09/21ALX Oncology to Participate in the Cantor Oncology, Hematology & HemeOnc Conference
GL
09/21ALX Oncology to Participate in the Cantor Oncology, Hematology & HemeOnc Conference
AQ
09/01ALX Oncology Announces Upcoming Investor Conference Participation
GL
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisionsFunds 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news

ALX Oncology : Corporate Presentation

06/07/2022 | 09:42am EDT

June 6, 2022

DISCLAIMER

This presentation contains forward-looking statements that involve substantial risks and uncertainties. Forward-looking statements include statements regarding future results of operations and financial position, business strategy, product candidates, planned preclinical studies and clinical trials, results of clinical trials, research and development costs, regulatory approvals, timing and likelihood of success, plans and objects of management for future operations, as well as statements regarding industry trends. Such forward-looking statements are based on ALX Oncology's beliefs and assumptions and on information currently available to it on the date of this presentation. Forward-looking statements may involve known and unknown risks, uncertainties and other factors that may cause ALX Oncology's actual results, performance or achievements to be materially different from those expressed or implied by the forward-looking statements. These and other risks are described more fully in ALX Oncology's filings with the Securities and Exchange Commission ("SEC"), including ALX Oncology's Annual Report on Form 10-K and other documents ALX Oncology files with the SEC from time to time. Except to the extent required by law, ALX Oncology undertakes no obligation to update such statements to reflect events that occur or circumstances that exist after the date on which they were made.

This presentation concerns product candidates that are under clinical investigation, and which have not yet been approved for marketing by the U.S. Food and Drug Administration. These product candidates are currently limited by federal law to investigational use, and no representation is made as to their safety or effectiveness for the purposes for which they are being investigated.

This presentation also contains estimates and other statistical data made by independent parties and by ALX Oncology relating to market size and growth and other industry data. This data involves a number of assumptions and limitations, and you are cautioned not to give undue weight to such estimates. In addition, projections, assumptions, and estimates of ALX Oncology's future performance and the future performance of the markets in which it operates are necessarily subject to a high degree of uncertainty and risk.

1

ADVANCING A HIGHLY DIFFERENTIATED IMMUNO-ONCOLOGY PIPELINE

ALX Oncology (Nasdaq: ALXO) is advancing a pipeline of candidates based on expertise in protein engineering and oncology led by the CD47 blocker, evorpacept, currently in phase 2 clinical trials

Evorpacept (myeloid checkpoint inhibitor) as a cornerstone therapy

Randomized phase 2 trials enrolling in 3 solid tumor indications: gastric/gastroesophageal cancer and 2 head and neck squamous cell carcinoma trials

Early clinical trials in 2 hematologic malignancies: myelodysplastic syndromes and acute myeloid leukemia

Continuing to broaden potential uses in new combinations and tumor types.

Building early stage pipeline

Ongoing IND-enabling development of ALTA-002 through 50/50 joint collaboration.

Early preclinical development of tumor-activated antibody platform.

Strong financial position

Cash and equivalents of $341.7M as of March 31, 2022.

Expected cash runway through mid-2024.

Collaboration partners

Merck, Eli Lilly, Zymeworks

2

EVORPACEPT'S BROAD CLINICAL DATA SUPPORTS ITS DIFFERENTIATED POTENTIAL

Evorpacept was designed to:

Evorpacept's clinical data shows promising

initial activity in:

Work in combinations

Target broad tumor indications

Be convenient and tolerable for patients

Antibodies

Checkpoint inhibitors

Chemotherapy

Solid tumors

Hematology

Flexible dosing schedule

Targets cancer cells

Evorpacept:

A phase 2 CD47 blocker

designed to be a

cornerstone of

cancer treatments

Solid tumor combinations:

GC

Herceptin

Gastric/Gastroesophageal

junction cancer

Herceptin + Cyramza + Paclitaxel

HNSCC

Keytruda

Head and neck

squamous cell carcinoma

Keytruda + 5FU + Platinum

Hematology combinations:

MDS

Azacitidine

Myelodysplastic syndromes

NHL

Rituximab

Non-Hodgkin's lymphoma

Flexibility and tolerability:

Dosing schedule

15 mg/kg QW,

30 mg/kg Q2W,

45 mg/kg Q3W,

60 mg/kg Q4W.

Tolerability profile

No dose-dependent cytopenias

3

ALX PIPELINE

Indication

HNSCC

Head And Neck Squamous Cell

Carcinoma

Studies

TUMORS

Gastric/Gastroesophageal

GC

Combination

SOLID

Junction Cancer

Urothelial Cancer

Evorpacept

HEMATOLOGY

NHL

Breast Cancer

MDS

Myelodysplastic Syndromes

AML

Acute Myeloid Leukemia

Non-Hodgkin's Lymphoma

ALTA 002*

Advanced Cancer

Combination Agent

Discovery

IND Enabling

Phase 1

Phase 2

Phase 3

Fast Track

Collaboration

Partner

Keytruda

(ASPEN-03)

Keytruda + 5FU + Platinum

(ASPEN-04)

Herceptin

(ASPEN-01)

Herceptin + Cyramza +

Paclitaxel (ASPEN-06)

Padcev

(ASPEN-07)

Zanidatamab

Azacitidine

(ASPEN-02)

Azacitidine + Venclexta

(ASPEN-05)

Rituximab

(ASPEN-01)

*SIRPα Toll-like receptor agonist antibody conjugate (TRAAC)

4

This is an excerpt of the original content. To continue reading it, access the original document here.

Disclaimer

ALX Oncology Holdings Inc. published this content on 06 June 2022 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 07 June 2022 13:41:06 UTC.


© Publicnow 2022
All news about ALX ONCOLOGY HOLDINGS INC.
09/21ALX Oncology to Participate in the Cantor Oncology, Hematology & HemeOnc Conference
GL
09/21ALX Oncology to Participate in the Cantor Oncology, Hematology & HemeOnc Conference
AQ
09/01ALX Oncology Announces Upcoming Investor Conference Participation
GL
08/26UBS Adjusts ALX Oncology Price Target to $31 From $37, Maintains Buy Rating
MT
08/16ALX Oncology's Evorpacept Picked for New Treatment Arm in Breast Cancer Trial
MT
08/16ALX Oncology and Quantum Leap Healthcare Collaborative™ Announce the Selection of..
PR
08/15Alx Oncology : Corporate Presentation
PU
08/15ALX Oncology Says Evorpacept Selected in Early-Stage Trial in Combination With Enhertu ..
MT
08/15ALX Oncology and Quantum Leap Healthcare Collaborative™ Announce the Selection of..
GL
08/15ALX Oncology Holdings Inc. and Quantum Leap Healthcare Collaborative Announces the Sele..
CI
More news
Analyst Recommendations on ALX ONCOLOGY HOLDINGS INC.
More recommendations
Financials (USD)
Sales 2022 - - -
Net income 2022 -126 M - -
Net cash 2022 247 M - -
P/E ratio 2022 -3,19x
Yield 2022 -
Capitalization 392 M 392 M -
EV / Sales 2022 -
EV / Sales 2023 -
Nbr of Employees 52
Free-Float 73,6%
Chart ALX ONCOLOGY HOLDINGS INC.
Duration : Period :
ALX Oncology Holdings Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends ALX ONCOLOGY HOLDINGS INC.
Short TermMid-TermLong Term
TrendsBearishNeutralBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 8
Last Close Price 9,63 $
Average target price 38,13 $
Spread / Average Target 296%
EPS Revisions
Managers and Directors
Jaume Pons President, Chief Executive Officer & Director
Peter S. García Chief Financial Officer
Corey S. Goodman Executive Chairman
Sophia Randolph Director & Chief Medical Officer
Michael Chang Vice President-Operations
Sector and Competitors
1st jan.Capi. (M$)
ALX ONCOLOGY HOLDINGS INC.-55.19%392
GILEAD SCIENCES, INC.-14.14%78 787
REGENERON PHARMACEUTICALS, INC.8.64%74 550
VERTEX PHARMACEUTICALS26.04%72 693
BIONTECH SE-50.21%31 192
WUXI APPTEC CO., LTD.-40.57%28 154